By Marie Daghlian
Giant technology firms see great potential for growth in the healthcare arena, as firms such as Microsoft (NASDAQ:MSFT), IBM, and Google (NASDAQ:GOOG) position themselves as players in the space. Oracle’s (NYSE:ORCL) $685 million all cash acquisition of Phase Forward, a leading data management provider for clinical trials and drug safety, is part of the world’s largest enterprise software company’s strategy to expand its reach in the healthcare arena. The deal builds on Oracle’s acquisition last year of California-based drug safety and risk management company Relsys International.
“The life sciences and healthcare industries are converging as they seek to control costs while accelerating patient-centered innovation,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences in a statement. “Phase Forward brings outstanding products and employees with significant expertise to Oracle that will help enable the delivery of personalized medicine and value-based healthcare.”
Phase Forward’s Integrated Clinical Research Suite manages clinical development and safety processes from phase 1 clinical trials through regulatory submission and post-approval monitoring, and according to the company, its technology has been used in more than 10,000 clinical trials by many large pharmaceutical companies and regulatory agencies.
Oracle is offering $17 per share in cash for the Waltham, Massachusetts-based company’s shares. Phase Forward will be folded into Oracle’s Health Sciences Global Business unit. The transaction, subject to stockholder and regulatory approval, is expected to close mid-2010.
Javelin Pharmaceuticals (JAV) broke its $96 million merger deal with Myriad Pharmaceuticals (OTCPK:MYRX) for a sweeter, and binding, merger offer from Hospira (NYSE:HSP) worth $141 million. Javelin and Myriad’s deal was a share exchange while Hospira offered to acquire all outstanding shares of Javelin for $2.20 per share in cash. Hospira will also provide Javelin with a $4.5 million working capital facility to fund Javelin until the merger is completed, provide $8.3 million to repay Javelin’s loan from Myriad, and $4.4 million to pay the break-up fee. Although Myriad had until midnight April 16 to respond with a better offer, the company has remained silent.
The deal will expand Hospira’s pipeline of specialty injectables. Javelin’s injectable pain drug Dyloject has been submitted to the U.S. Food and Drug Administration for marketing approval and the company expects an answer by the beginning of October.
Devices that help manage diabetes are hot. Just weeks after Sanofi-Aventis (NYSE:SNY) signed a development deal with U.S. blood glucose monitor developer Agamatrix, Roche (OTCQX:RHHBY) also boosted its position in the space by buying Medingo, a unit of Israeli holding company Elron Electronics (ELRN), for an upfront payment of $160 million as well as up to 25 percent of the upfront payment in performance milestones. Medingo is developing a semi-disposable insulin patch pump that consists of two parts: a semi-disposable insulin dispensing patch and a remote control so the patient can control insulin delivery.
“With this acquisition we will broaden our portfolio of innovative insulin delivery technologies and strengthen our position as a leading player in the diabetes care business,” said Roche Diagnostics Chief Operating Officer Daniel O'Day in a statement.
Roche is already a leader in the insulin delivery system global market where its main competitors are Bayer, Johnson & Johnson (NYSE:JNJ) and Abbott (NYSE:ABT) in pumps and blood glucose monitoring, according to the company. A global launch is expected in 2012.
Teva Pharmaceuticals (NYSE:TEVA) has been busy, not only expanding its presence in generics, but also with its expansion into branded drugs. The Isreali pharma entered into a research and exclusive license agreement with U.S. biotech Mersana Therapeutics, a cancer therapeutic platform company, to develop and commercialize XMT-1107, a novel fumagillin analog, in all indications, including cancer. Mersana plans to initiate a phase 1 clinical trial for XMT-1107 in the second quarter of 2010. As part of their agreement, Teva will receive an exclusive license to XMT-1107 for all indications worldwide, excluding Japan, for which Mersana will retain rights. Mersana will be eligible to receive up to $334 million if all development, regulatory and commercial milestones are met across several indications. Mersana will be eligible to receive royalties on net sales worldwide. Teva will cover all development costs for XMT-1107, excluding those specific to Japan.
Mersana Therapeutics employs a biodegradable polymer platform, Fleximer, to generate a pipeline of novel compounds with the potential to address multiple oncology indications. XMT-1107 is a conjugate of Fleximer and a novel analog of fumagillin, an angiogenesis inhibitor with a mechanism of action distinct from agents that principally target vascular endothelial growth factor. Fumagillins come with safety concerns that Mersana believes its flexible biopolymer conjugate technology can resolve.
Cambridge, Massachusetts-based biotech Agios Pharmaceuticals entered into a global strategic collaboration with Celgene (NASDAQ:CELG) focused on targeting cancer metabolism using Agios’ cancer metabolism research platform. The platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can “starve” the cancer. Under the terms of their agreement, Agios will get $130 million upfront that includes an equity investment by Celgene. Agios will lead discovery and early translational development for all cancer metabolism programs. Celgene has an exclusive option to license any resulting clinical candidates at the end of phase 1, and will lead and fund global development and commercialization of licensed programs. On each program, Agios may receive up to $120 million in milestones as well as royalties on sales, and may also participate in the development and commercialization of certain products in the U.S.
German biotech, AiCuris, a Bayer Healthcare spin-out, raised $75 million in its second round of financingfor further development of its antiviral and antibacterial compounds. The main investor is the Santo Holding of Andreas and Thomas Strüngmann, the former owners of the generics company Hexal. AiCuris develops novel, resistance-breaking drugs for the treatment of HCMV, herpes, Hepatitis B, HIV and Hepatitis C as well as resistant Gram positive and Gram negative bacterial infections in hospitals. The company recently demonstrated, in a mid-stage study, the efficacy and safety of its lead treatment against Human Cytomegalovirus, a virus that often leads to complications after organ or bone marrow transplantations and is also a major infectious cause of birth defects and neurological sequels including hearing loss after birth.
Personalized cancer medicine company Foundation Medicine completed a $25 million Series A financing led by Third Rock Ventures. The Massachusetts company aims to bring comprehensive cancer genome analysis into routine clinical care. Proceeds from the financing will be used to develop clinical laboratory tests -- using next generation sequencing and other advanced technologies -- that will broadly analyze the relevant tumor genomic and other molecular information in individual patients' cancers and connect it with a knowledge base of clinical data to help oncologists personalize treatment.
Finally, Neovacs completed its initial public offering on Alternext by NYSE Euronext Paris. The response was underwhelming, possibly because its pipeline consists of three compounds in early-stage development. The French biotech, which develops immunotherapies for autoimmune and chronic diseases, sold 2 million shares at $6.48 per share to raise $13.5 million. The company had originally proposed selling 4.4 million shares at a price range of $6.50 to $7.50. It will begin trading under the symbol ALNEV on April 21.
|WEEK ENDING APRIL 16, 2010 GLOBAL VENTURE FINANCINGS|
|Company||Location||Amount Raised ($M)||Principal Focus|
|Axerion Therapeutics||New Haven, CT||0.75||Neurology|
|MGB Biopharma||Scotland, United Kingdom||3.00||Infectious|
|AltheaDx||San Diego, CA||6.00||Companion Diagnostics|
|Articulinx||Cupertino, CA||10.00||Medical devices|
|biospace med||Paris, France||18.00||Medical imaging|
|Beijing YiCheng Bioelectronics||Beijing, China||10.30||Blood glucose monitoring|
|Exos||Arden Hills, MN||0.93||Medical devices|
|Foundation Medicine||Cambridge, MA||25.00||Cancer genomics|
|Avraham Pharmaceuticals||Jerusalem, Israel||9.00||Neurology|
|Crossbeta Biosciences||Utrecht, Netherlands||2.70||Protein engineering|
|Nautilus Neurosciences||Bridgewater, NJ||N/A||Specialty pharma|
|Catabasis Pharmaceuticals||Cambridge, MA||7.70||Inflammatory, metabolic|
|Ambit Biosciences||San Diego, CA||12.00||Oncology|
|Allylix||San Diego, CA||3.00||Specialty chemicals|
|TOTAL RAISED US||$65.38|
|TOTAL RAISED EX-US||$119.50|
|GRANTS AND CONTRACTS|
|Company||Funding/Contracting Agency||Amount ($M)||Principal Focus|
|Genocea Biosciences||U.S. Army Medical Research and Materiel Command||2.70||Malaria vaccine|
|Corgenix Medical||NIH||N/A||Viral diagnostics|
|PROLOR Biotech (Israel)||israeli Office of Chief Scientist||1.60||Endocrine|
|Nano Retina (Israel)||BIRD Foundation||0.75||Bionic retina|
|HemoSchear||NIH NHLBI SBIR||N/A||Pathway analysis|
|PolyTherics (United Kingdom)||Technology Strategy Board||0.16||Protein engineering|
|Company||Funding/Contracting Agency||Amount ($M)||Financing Type|
|Ondine Biopharma (Canada)||TSX: OBP||0.75||PIPE|
|Osta Biotechnologies (Canada)||TSX-V:OBI||0.50||PIPE|
|CardioComm Solutions (Canada)||TSX-V:EKG||0.50||PIPE|
|ALDA Pharmaceuticals (Canada)||TSX-V:APH||0.50||PIPE|
|Benitec Limited (Australia)||ASX:BLT||6.00||Debt|
|TOTAL PUBLIC FINANCINGS-US||$55.03|
|Acquirer||Target||Deal Value in $M||Focus|
|Roche (Switzerland)||Medingo (Elron Electronics-Israel)||$200.00||Medical devices|
|PerkinElmer (NYSE:PKI)||Signature Genomic Laboratories||$90.00||Diagnostics|
|ChromoCure||Genome Research Group||$25.00||Cancer Detection Technology|
|Pfizer (NYSE:PFE)/Pfizer Investments Netherlands||Pfizer Limited India||N/A||Biopharmaceuticals|
|JW Asset Management and Edward Schutter||Arbor Pharmaceuticals||N/A||Pediatric medicine|
|Thermo Fisher Scientific (NYSE:TMO)||Proxeon (Denmark)||N/A||Tools/Technology|
|Oracle||Phase Forward||$685.00||Healthcare IT|
|Company/Licensee||Company/Licenser||Deal Value in $M||Focus|
|Upsher-Smith Laboratories||Proximagen Neuroscience (United Kingdom)||N/A||Neurology license|
|Abbott Laboratories||Axis-Shield (United Kingdom)||N/A||Diagnostics partnership|
|Orient Europharma (Taiwan)||Medinox||N/A||Renal drug collaboration|
|miRagen Therapeutics||RXi Pharmaceuticals (OTC:RXII)||N/A||microRNA research collaboration|
|Mirna Therapeutics||Rxi Pharmaceuticals||N/A||Oncology research collaboration|
|Takeda Pharmaceuticals (Japan)||Metabolex||N/A||Metabolic research collaboration|
|Teva Pharmaceuticals (Israel)||Mersana Therapeutics||$334.00||Oncology drug license|
|Celgene||Agios Pharmaceuticals||$130.00||Oncology collaboration and license option|
|Mauna Kea Technologies (France)||EndoControl (France)||$22.10||Endoscopy research collaboration|